Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773612 | 0.79 | USP2 (0.38) | USP2SMN1; SMN2BCHEFAAHCHRM2 | |
| SCHEMBL29250309 | 0.77 | USP2 (0.42) | USP2SMN1; SMN2BCHEFAAHCHRM2 | |
| SCHEMBL4063731 | 0.76 | USP2 (0.32) | USP2SMN1; SMN2BCHEFAAHCHRM2 | |
| SCHEMBL1616176 | 0.75 | USP2 (0.34) | USP2SMN1; SMN2BCHE | |
| SCHEMBL2338031 | 0.71 | — | — | |
| SCHEMBL3759743 | 0.70 | — | — | |
| SCHEMBL5753658 | 0.69 | USP2 (0.35) | USP2SMN1; SMN2BCHECHRM2CHRM1 | |
| SCHEMBL3354765 | 0.68 | USP2 (0.40) | USP2SMN1; SMN2BCHEFAAHCHRM2 | |
| SCHEMBL29029079 | 0.68 | USP2 (0.36) | USP2SMN1; SMN2BCHEFAAHCHRM2 | |
| SCHEMBL5858067 | 0.68 | USP2 (0.40) | USP2SMN1; SMN2BCHECHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653438-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025051241-A1 | MACROCYCLIC COMPOUND AND ANTIBODY-DRUG CONJUGATE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| WO-2023142641-A1 | PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都苑东生物制药股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-113166103-B | EGFR inhibitor and application thereof | 江苏先声药业有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-113166103-A | EGFR inhibitor and application thereof | 江苏先声药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-1663996-B1 | (THIO)CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2012-06-20 | — | — | EP | disclosed |
| EP-1794122-B1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2011-05-04 | — | — | EP | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | disclosed |
| EP-1966215-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| EP-1794122-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060229297-A1 | (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2006-10-12 | — | — | US | disclosed |
| EP-1663996-A1 | (THIO)CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006023467-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005012266-A1 | (THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | USP2 1652/4885SMN1; SMN2 702/4885BCHE 1201/4885 |
| US-20060229297-A1 | (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists | DRD3, DRD2, TACR2 | USP2 1995/4885SMN1; SMN2 4660/4885BCHE 1898/4885 |
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK2A3, CSNK1G3, CSNK1G1 | USP2 1394/4885SMN1; SMN2 2775/4885BCHE 404/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | USP2 1652/4885SMN1; SMN2 702/4885BCHE 1201/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | USP2 1652/4885SMN1; SMN2 702/4885BCHE 1201/4885 |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK1G3, CSNK2A3, CSNK1E | USP2 1520/4885SMN1; SMN2 3376/4885BCHE 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.